Where I see patients (1)
Selected research
-
Efficacy and Safety of Daratumumab in Intermediate/High-risk Smoldering Multiple Myeloma: Final Analysis of CENTAURUS.
Blood
-
MRD-negative duration following latest line of therapy predicts long-term PFS in real-world multiple myeloma patients.
Blood advances
-
Author Correction: Mobilization strategies with and without plerixafor for autologous stem cell transplant in patients with multiple myeloma.
Bone marrow transplantation
Contact me
- Request appointment
- Refer a patient
- (415) 353-2421